Olmesartan medoxomil treatment is associated with decreased plasma B-type natriuretic peptide levels in patients on hemodialysis

What Was Tested

This controlled clinical trial looks at BNP (Nesiritide).

Who Took Part

The study group was 24 patients.

By PubMed's age tags, the people studied were middle-aged adults, older adults and people over 80, both men and women.

This preliminary, observational, open-labeled prospective study included 24 patients on HD who were assigned to one group treated with OM (n = 14) or to an age-matched control group that was conventionally treated (n = 10).

Blood pressure (BP) was monitored in the morning and evening of a non-HD day and before each HD session, and plasma BNP, plasma aldosterone (PAC), plasma active renin (PARC), and OM concentrations were measured at baseline, 4, and 8 weeks after treatment.

How the Study Was Run

The researchers set it up as an open-label study.

Being open-label, the BNP (Nesiritide) study did not mask who received what.

What Was Measured

The subject headings attached to it are Aldosterone, Angiotensin II Type 1 Receptor Blockers, Hypertension, Imidazoles, Kidney Failure, Chronic, Natriuretic Peptide, Brain and Olmesartan Medoxomil.

What This Means in Plain Language

The paper is an open-label study of BNP (Nesiritide) in 24 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2012 (Clinical and experimental hypertension (New York, N.Y. : 1993)), a journal based in England.

More context: the BNP (Nesiritide) compound page, all human trials.